Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer
Michael P. Chu(Sheba Medical Center), Michael B. Sawyer(University of Alberta), Dennis J. Slamon(University of California, Los Angeles), Vincent Houé(Translational Research in Oncology), Zev A. Wainberg(University of California, Los Angeles), Karen Afenjar(Translational Research in Oncology), S. Khan‐Wasti(GlaxoSmithKline (United Kingdom)), Andrew Scarfe(Cancer Institute (WIA)), Shukui Qin(81th Hospital of PLA), Neil Chua(Alberta Cancer Foundation), Yung‐Jue Bang(Seoul National University), Sheryl Koski(AstraZeneca (Australia)), Julie Price Hiller, Karen L. King, Paulo M. Hoff(Translational Research in Oncology), Alberto F. Sobrero(Ospedale Policlinico San Martino), Yingjie Huang, Jennifer L. Spratlin(University of Alberta), J. Randolph Hecht(Ontario Institute for Cancer Research), Karen Mulder
Cited by 106
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k